Advanced dispersion technology.
Pharmako’s LipiSperse® is an advanced cold water dispersion technology which allows lipophilic active ingredients with otherwise relatively low bioavailability and poor solubility in water, to be easily dispersed in cold water, thereby increasing their bioavailability and uptake in the body.
Advantages of utilising LipiSperse® in your product’s formulation:
• higher active loads • improved functionality • enhanced absorption.
Standard lipophilic absorbtion.
Lipophilic active ingredients provide challenges from a formulation and bioavailability perspective. Often improving bioavailability leads to decreased active load in final formulations.
The LipiSperse® solution.
LipiSperse® created cold water dispersible (CWD) powders are specifically designed to increase the bioavailability and functionality of lipophilic
actives. In aqueous environments (such as the stomach), the Lipisperse® enhanced active particles freely disperse, further enhancing the body’s natural digestive process.
Recent pharmacokinetic studies have shown a significant increase in bioavailability of various lipophilic actives.
LipiSperse® is made in Australia from pharmacopoeial grade ingredients, under cGMP standards.
LipiSperse® formulations can be customised:
• to optimise diverse active ingredient(s) bioavailability.
• for customer requirements.
• for regulatory frameworks.
• for dosage format(s).
LipiSperse®’s enhanced bioavailability is scientifically validated through:
• pharmacokinetic studies.
• clinical trials.
Pharmako can develop LipiSperse® formulations for use in multiple product sectors and applications including:
• dietary supplements,
• food and beverage.
LipiSperse® is approved and customised for active Ingredients such as:
LipiSperse® is a patent-pending technology and a registered trade mark owned exclusively by Pharmako Biotechnologies Pty Ltd.